A Phase III, randomised study of aspirin and esomeprazole chemoprevention in Barrett's metaplasia.

Trial Results

The results of the AspECT trial have been accepted for presentation at the ASCO conference. The full final text of the abstract will be posted online at 0730 E.T. (1130 GMT) on Monday 4th June.

Click Here to view 

Study Objectives

To assess whether intervention with aspirin and/or high dose PPI therapy results in decreased mortality or conversion rate from Barrett’s metaplasia to adenocarcinoma or high grade dysplasia.